Purpose We compared a cohort of Haitian immigrants with residents in Haiti with breast cancer (BC) to evaluate the effects of location on presentation, treatment, and outcomes.

Patients and Methods Participants were Haitian women with BC living in Miami who presented to the University of Miami/Jackson Memorial Hospital and women with BC living in Haiti who presented to the Innovating Health International Women’s Cancer Center. The primary outcome was the relationship between location, cancer characteristics, and survival. The secondary objective was to compare our results with data extracted from the SEER database. Cox regression was used to compare survival.

Results One hundred two patients from University of Miami/Jackson Memorial Hospital and 94 patients from Innovating Health International were included. The patients in Haiti, compared with the patients in Miami, were younger (mean age, 50.2 v 53.7 years, respectively; \( P = .042 \)), presented after a longer duration of symptoms (median, 20 v 3 months, respectively; \( P < .001 \)), had more advanced stage (44.7% v 25.5% with stage III and 27.6% v 18.6% with stage IV BC, respectively), and had more estrogen receptor (ER)–negative tumors (44.9% v 26.5%, respectively; \( P = .024 \)). The percentage of women who died was 31.9% in Haiti versus 17.6% in Miami. Median survival time was 53.7 months for women in Haiti and was not reached in Miami. The risk of death was higher for women in Haiti versus women in Miami (adjusted hazard ratio, 3.09; \( P = .0024 \)).

Conclusion Women with BC in Haiti experience a significantly worse outcome than immigrants in Miami, which seems to be related to a more advanced stage and younger age at diagnosis, more ER-negative tumors, and lack of timely effective treatments. The differences in age and ER status are not a result of access to care and are unexplained.

INTRODUCTION
In the past 20 years, breast cancer (BC) diagnosis and death has risen in low- and middle-income countries (LMICs), and BC is the most frequent cause of cancer death in women in most regions.\(^1\)\(^-\)\(^3\) Disparities in BC outcomes have been reported for different races and ethnicities and income levels within a country despite adjusting for known confounders.\(^4\) These differences are multifactorial and are related to differences not only in tumor biology but also in screening practices, access to care, and overall socioeconomic status. However, accurate registries are missing for many regions, and characterization of how migration status influences BC characteristics and survival in different populations has not yet been demonstrated.

The Haitian population constitutes 1.5% of immigrants in the United States and is the fourth largest group from the Caribbean after Cuba, the Dominican Republic, and Jamaica.\(^5\) Many Afro-Caribbean immigrants live in south Florida. In this study, we compared Haitian immigrants with residents in Haiti diagnosed with BC to evaluate the effects of geographic location on presentation, treatment, and outcomes.

PATIENTS AND METHODS
Study Design and Study Population
This was a retrospective cohort study. The study population included Haitian women, living in Miami, who presented to the University of Miami (UM)/Jackson Memorial Hospital (JMH) between...
2008 and 2014 with a new diagnosis of BC and women in Haiti who presented to the Innovating Health International Women’s Cancer Center (IHI-WCC) in Port-au-Prince from 2013 to 2015 for care. Patients were identified by a review of the UM/JMH BC clinic patient roster and the IHI-WCC program database. All patients were confirmed by chart review. The institutional review board at UM and the Haitian National Bioethics Committee approved the study, data collection, transmission methods, and storage protocols.

JMH is a university-based, tertiary, safety net hospital in Miami, Florida. It is estimated that more than 40% of Haitians in Florida live in Miami-Dade County and that 8% of the patients attending the JMH BC clinic are Haitian. Haiti has a population of 11 million and no fellowship-trained oncologists. This clinical and research program in Haiti is supported through a collaboration of the US-based nonprofit IHI and the University of Florida College of Medicine. IHI-WCC, working with the Haitian Ministry of Health, partners in a public and private hospital that serves as an urban tertiary center and is the second largest BC program in the country.

Definitions and End Points

Data were collected on patient demographics, disease and treatment characteristics, and clinical outcome. Slightly more than half of biopsies from Haiti (52%) were sent to the United States for pathology and immunohistochemistry, but not all of those had human epidermal growth factor receptor 2 (HER2) expression performed because it does not affect treatment decisions in Haiti as a result of the lack of trastuzumab. Those biopsies performed in Haiti reported histopathologic diagnosis but not estrogen receptor (ER), progesterone receptor (PR), or HER2 statuses.

Follow-up was defined as time in months from BC diagnosis to date of death or last date of follow-up. Progression-free survival (PFS) was defined as the time from cancer diagnosis to relapse, disease progression, new contralateral BC, or death from any cause; patients who were alive and progression free were censored at the date of last documented progression-free status. Overall survival (OS) was defined as the time from cancer diagnosis to death from any cause; follow-up for alive patients was censored at date of last contact. Death was confirmed by clinical records and the Social Security Death Index for patients in Miami and by direct contact with family members for patients in Haiti.

Historical Comparison Data

We extracted data from the SEER-18 registries research database. We selected women diagnosed with BC from 2008 to 2012 (American Joint Committee on Cancer, sixth edition, stage 0 to IV), with an age at diagnosis ≥ 18 years and race or ethnicity of non-Hispanic white (NHW) or non-Hispanic black (NHB). These race/ethnicity groups were derived from the SEER variables race code (RAC_RECY) and the North American Association of Central Cancer Registries Hispanic/Latino Identification Algorithm recode of Hispanic origin. We selected patients on the basis of ER and PR status, who were then classified as both ER and PR negative or as ER or PR positive. These selection criteria yielded a case listing of 35,285 NHB and 232,072 NHW women to compare with our two cohorts of Haitian women. In this selected SEER data set, we derived triple-negative status. Note that ERBB2 status (formerly HER2 or HER2/neu) is available for NHW women to compare with our two cohorts of Haitian women. In this selected SEER data set, we derived triple-negative status. Note that ERBB2 status (formerly HER2 or HER2/neu) is available in SEER for cases diagnosed in 2010 and later.

Statistical Analysis

Data were analyzed by complete case analysis. Patient-related and cancer-related variables were described as categorical, discrete, or continuous variables using the corresponding descriptive statistics such as absolute and relative frequencies, mean, median, range, interquartile range, and standard deviation (SD); 95% CIs or SEs were reported as appropriate. Comparisons between the cohorts were performed using the t test or the nonparametric Mann-Whitney-Wilcoxon test for continuous variables and the Fisher’s exact test or the $x^2$ test for categorical variables.

OS curves were estimated using the Kaplan-Meier method. The 95% CIs for time-specific rates and median OS were estimated using the log-log transform method and the Greenwood’s variance. The log-rank test and Cox proportional hazards regression analysis were used to compare OS between women in Haiti and in Miami. The method by Fine and Gray was used to estimate the effect of study cohort on the risk of death from BC, taking into account death from other causes as the competing risk. Statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC).

RESULTS

Baseline Patient Characteristics

One hundred two patients were included in the Miami cohort, and 98 patients were included in the Haiti cohort. Demographic, cancer-related, and treatment characteristics are listed in Table 1.
Table 1. Demographic and Breast Cancer–Related Characteristics of Study Cohorts

| Characteristic                  | Haitians in Haiti | Haitians in Miami | P     |
|--------------------------------|------------------|------------------|-------|
|                                | No. (n = 94)     | No. (n = 102)    |       |
|                                | %                | %                |       |
| Age at diagnosis, years        |                  |                  |       |
| < 40                           | 21 (22.3)        | 8 (7.8)          | .024  |
| 40-49                          | 27 (28.7)        | 27 (26.5)        |       |
| 50-59                          | 27 (28.7)        | 40 (39.2)        |       |
| > 60                           | 19 (20.2)        | 27 (26.5)        |       |
| < 50                           | 48 (51.1)        | 35 (34.3)        | .018  |
| > 50                           | 46 (48.9)        | 67 (65.7)        |       |
| Mean                           | 50.2             | 53.7             | .042  |
| SD                             | 12.9             | 11.1             |       |
| Median                         | 48.5             | 54               |       |
| Range                          | 27-89            | 27-88            |       |
| BMI, kg/m²                     |                  |                  | < .001|
| < 25                           | 41 (47.7)        | 18 (18.2)        |       |
| 25-29.99                       | 29 (33.7)        | 33 (33.4)        |       |
| > 30                           | 16 (18.6)        | 48 (48.5)        |       |
| Mean                           | 25.9             | 30.0             | < .001|
| SD                             | 5.1              | 5.4              |       |
| Symptoms before presentation   |                  |                  |       |
| Yes                            | 87 (92.6)        | 82 (80.4)        | .014  |
| No/NA                          | 7 (7.4)          | 20 (19.6)        |       |
| Time with symptoms, months     |                  |                  | < .001|
| Mean                           | 26.6             | 6                |       |
| SD                             | 24.3             | 7.7              |       |
| Median                         | 20               | 3                |       |
| Range                          | 1-120            | 0.5-48           |       |
| Cancer stage                   |                  |                  |       |
| 0 (DCIS)                       | 1 (1.1)          | 14 (13.7)        | < .001|
| I                              | 2 (2.1)          | 15 (14.7)        |       |
| II                             | 23 (24.5)        | 28 (27.5)        |       |
| III                            | 42 (44.7)        | 26 (25.5)        |       |
| IV                             | 26 (27.6)        | 19 (18.6)        |       |
| 0/I/II                         | 26 (27.7)        | 57 (55.9)        | < .001|
| III                            | 42 (44.7)        | 26 (25.5)        |       |
| IV                             | 26 (27.6)        | 19 (18.6)        |       |
| Receptor status                |                  |                  |       |
| ER                             | 49               |                  | .024  |
| Negative                       | 22 (44.9)        | 27 (26.5)        |       |
| Positive                       | 27 (55.1)        | 75 (73.5)        |       |
| PR                             | 34               |                  | .013  |
| Negative                       | 22 (64.7)        | 41 (40.2)        |       |
| Positive                       | 12 (35.3)        | 61 (59.8)        |       |

(Continued on following page)
The mean age at BC diagnosis was 53.7 years (range, 27 to 88 years) for women in Miami compared with 50.2 years (range, 27 to 89 years) for women in Haiti ($P = .042$). Mean body mass index was 25.9 kg/m$^2$ (SD, 5.1 kg/m$^2$) in Haiti compared with 30 kg/m$^2$ (SD, 5.4 kg/m$^2$) in Miami ($P < .001$). One patient from Miami had bilateral BC at the time of presentation, and six patients presented with a new contralateral second primary tumor. Three patients in Haiti presented with bilateral BC. In Miami, all patients had ER, PR, and HER2 status ascertained at diagnosis, whereas only 52%, 36.2%, and 26.6% of the women living in Haiti had ER, PR, and HER2 status ascertained, respectively. Among those with known receptor status in Miami and Haiti, ER status was positive in 73.5% and 55.1% of patients, respectively ($P = .024$), and HER2 status was positive in 19.6% and 28% of patients, respectively ($P = .358$). There was a significant difference in the disease stage between patients in Miami and Haiti ($P < .001$), as follows: 13.7% and 1.1% with stage 0 (ductal carcinoma in situ), 14.7% and 2.1% with stage I, 27.5% and 24.5% with stage II, 25.5% and 44.7% with stage III, and 18.6% and 27.6% with stage IV, respectively.

In Miami, 80% of patients presented with symptoms, whereas 20% of patients presented after abnormal screening. In Haiti, 92.6% of the patients presented with a self-detected mass. The median time from onset of symptoms before first health care evaluation was 3 months (range, 0.5 to 48 months) in Miami compared with 20 months (range, 1 to 120 months) in Haiti ($P < .001$).

### Clinical Outcomes After Treatment

**PFS.** In Miami, 30 patients had progressive disease, including 14 (16.90%) of 83 patients who

### Table 1. Demographic and Breast Cancer–Related Characteristics of Study Cohorts (Continued)

| Characteristic                          | Haitians in Haiti | Haitians in Miami | $P$ |
|-----------------------------------------|------------------|------------------|-----|
| **HER2**                                |                  |                  |     |
| No. (n = 94)                            |                  | No. (n = 102)    |     |
| Negative                                | 25               | 18               | .358|
| Positive                                | 7                | 7                |     |
| **Treatment**                           |                  |                  |     |
| Surgery                                 | 73               |                  |     |
| Mastectomy                              | 44               | 42               | < .001|
| Lumpectomy                              | 6                | 36               |     |
| None/palliative/unknown (only in Haiti) | 23               | 24               |     |
| Neoadjuvant chemotherapy                |                  |                  | .209|
| Yes                                     | 25               | 26               |     |
| None/unknown (only in Haiti)            | 48               | 76               |     |
| Adjuvant chemotherapy                   |                  |                  | < .001|
| Yes                                     | 48               | 35               |     |
| None/unknown (only in Haiti)            | 25               | 67               |     |
| Radiation                               |                  |                  | < .001|
| Yes                                     | 7                | 59               |     |
| None/unknown (only in Haiti)            | 66               | 43               |     |
| Hormonal therapy* in ER-/PR-positive patients | 27               | 75               | .565|
| Yes                                     | 19               | 57               |     |
| None/unknown (only in Haiti)            | 8                | 18               |     |
| HER2-directed therapy in HER2-positive patients | 7                | 20               | < .001|
| Yes                                     | 0                | 15               |     |
| None                                    | 7                | 5                |     |
| **Abbreviations:** DCIS, ductal carcinoma in situ; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; NA, not available; PR, progesterone receptor; SD, standard deviation. |

*Additional 12 patients with unknown ER status received hormonal therapy.
were initially diagnosed with stage 0 to III disease and 16 (84.2%) of 19 patients with metastatic disease. For patients in Miami who presented with stage 0 to III disease, four patients (4.8%) experienced relapse, six patients experienced progression on neoadjuvant therapy, and two patients refused therapy. Two patients developed a new contralateral BC. The median PFS was not reached for those treated with curative intent, whereas it was 15.3 months (95% CI, 7.9 to 26.6 months) for patients with metastatic disease (Fig 1).

In the cohort from Haiti, 11 patients experienced progression (median time to progression, 24 months; range, 5 to 80 months), and 16 patients died as a result of BC (median OS, 11 months; range, 0.2 to 23 months). Length of PFS is difficult to compare between the two groups because the progression of disease was much more likely to be detected by physical exam or symptoms in Haiti, whereas in the United States, the use of staging computed tomography scans is common. However, this would underestimate the difference rather than increase it, so it seems that the PFS is much shorter in Haiti for patients without metastatic disease.

OS. OS was significantly different in the two cohorts ($P < .001$). In Miami, 18 (17.6%) of 102 patients died, 15 (14.7%) from BC (10 patients with initial metastatic disease and five with initial curable disease) and three from a second malignancy (colorectal cancer, bladder cancer, and lung cancer). The median length of follow-up was 42 months (interquartile range, 28 to 57 months) among 84 alive patients at last contact. In Haiti, 23 (31.9%) of 72 patients died of BC, 14 (19.4%) with initial metastatic disease and nine (12.5%) with curable disease.

The Kaplan-Meier estimate of median OS was 53.7 months for patients with curable disease in Haiti and was not reached in for patients in Miami. For patients with metastatic disease, the median OS was 38.5 months in Miami compared with 18.3 months in Haiti (Fig 1 and Table 2). In univariable analysis, the risk of death was higher for women in Haiti than women in Miami (hazard ratio, 4.02; 95% CI, 2.10 to 7.68; $P < .001$; Table 2). As reported in Table 2, results from analysis in stage 0 to III patients, taking into account the three deaths from other causes as competing risks, estimated the risk of death as 10.28-fold higher in Haiti versus Miami (adjusted hazard ratio, 10.28; 95% CI, 3.08 to 34.33; $P < .001$).

Comparison Analysis With Historical Data From SEER Database

Table 3 lists the main characteristics of the subgroups. The age at diagnosis was significantly different between all groups, with women in Haiti presenting at a mean age of 50.2 years, Haitian women in Miami at 53.7 years, NHB women at 58.8 years, and NHW women at 62.4 years. Stage IV disease was seen in 27.6% of women living in Haiti, 18.6% of women living in Miami, 5.9% of NHB women, and 3.8% of NHW women. The rate of negative ER and PR status was 35.7% for women in Haiti, 26.5% for women in Miami, 25.3% for NHB women, and 14.9% for NHW women. HER2 was positive for 28% of women in Haiti, 19.6% of women in Miami, 19.7% of NHB women, and 16.1% of NHW women. Triple-negative disease was seen in 17.5% of women in Haiti, 21.6% of women in Miami, 11.9% of NHB women, and only 5.5% of NHW women.

**DISCUSSION**

We found that Haitian women with BC living in Haiti experience a significantly worse outcome than Haitian women who were born in Haiti and immigrated to Miami. This may not be surprising as a result of the lack of screening practices, limited pathologic evaluation for receptor status, poor access to care, delays in treatment, and unavailability of radiation and HER2-targeted therapy in Haiti. However, there were differences in age at presentation and intrinsic tumor characteristics that confer a poorer prognosis that cannot be explained by access to care.

Cancer care differences between LMICs and high-income countries (HICs) are striking. More than 70% of patients in most HICs are diagnosed at stage I or II, compared with 20% to 50% of patients...
in the majority of LMICs. Stage at presentation in Haiti was skewed to stage III and IV, with only 27.7% of women presenting with stage 0 to II. For Haitians living in Miami, this percentage was better (55.9%), but was still lower than for NHB women (80.7%) and NHW women (87.1%). Delays in diagnosis have been associated with more advanced stage and worse prognosis. In a review of delays comparing HICs with LMICs, where BC total delay is defined as more than 3 months between symptom discovery and the beginning of treatment, it was found that among HICs, the median OS times were 30 to 48 days and more than 60% of patients began treatment less than 3 months after symptom discovery. In comparison, the median time of symptom duration before treatment for LMICs was 5.5 to 8 months, and less than 30% of patients started treatment in less than 3 months. Women in Haiti had extreme delays in diagnosis even by LMIC standards, with a median time from onset of symptoms before first health care evaluation of 20 months. Although living in an HIC, Haitian women living in Miami still experienced both patient delays (median time between symptom onset and presentation of 3 months) and provider delay (median time from the initial health care encounter to treatment of 72 days). Only 18.6% of patients started treatment within 4 months of symptom discovery, and this remains outside of the average for HICs.

Access and quality of care deficiencies are multifactorial. Patients in Haiti have no access to screening, but even after they moved to an HIC, their utilization rates remained suboptimal. A recent report documents that only 58% of Haitian women living in the United States who should undergo screening actually do so. This
Table 2. Summary of Death Events, OS, and Death From Breast Cancer Between the Two Study Cohorts, Overall and by Stage at Disease Presentation

| Survival                  | All Patients          | Stage 0-III Patients | Stage IV Patients |
|---------------------------|-----------------------|----------------------|-------------------|
|                           | Haiti | Miami | Haiti | Miami | Haiti | Miami |
| No. of patients           | 72    | 102   | 49    | 83    | 23    | 19    |
| No. of deaths             | 23    | 18*   | 9     | 8*    | 14    | 10    |
| OS                        |        |       |       |       |       |       |
| Median OS, months (95% CI)| 53.7 (23.1 to 65.6)  | NE                  | 53.7 (23.1 to NE) | NE      | 18.3 (11.7 to 38.5) | 38.5 (15.4 to NE) |
| 4-year OS, % (95% CI)     | 50.1 (28.6 to 68.2)  | 80.8 (69.7 to 88.2) | 70.6 (45.5 to 85.8) | 91.9 (81.5 to 96.6) | 22.6 (4.2 to 49.6) | 39.2 (15.1 to 62.8) |
| Unadjusted HR (95% CI)    | 4.02 (2.10 to 7.68)  | Ref                 | 5.26 (1.91 to 14.52) | Ref     | 2.10 (0.91 to 4.82) | Ref     |
| Adjusted HR§ (95% CI)     | 3.09 (1.49 to 6.40)  | Ref                 | 7.24 (2.15 to 24.34) | Ref     | 2.10 (0.83 to 5.31) | Ref     |
| Survival from breast cancer |       |       |       |       |       |       |
| Unadjusted HR (95% CI)    | 4.83 (2.51 to 9.28)  | Ref                 | 8.19 (2.96 to 22.67) | Ref     |
| Adjusted HR¶ (95% CI)     | 3.46 (1.65 to 7.24)  | Ref                 | 10.28 (3.08 to 34.33) | Ref     |

NOTE. In all patients, patients with stage 0 to III disease, and patients with stage IV disease, univariable models were based on 174, 132, and 42 patients, respectively, and multivariable models were based on 163, 124, and 42 patients, respectively, as a result of missing data.

Abbreviations: HR, hazard ratio; NE, not evaluable; OS, overall survival; Ref, reference.

*Three deaths occurred from other causes at the following times from diagnosis: 16.1 months (stage II, 53 years old), 49.3 months (stage 0, 73 years old), and 59.2 months (stage I, 72 years old).

†P value from log-rank test comparing the two cohort OS curves estimated by the Kaplan-Meier method.

‡P value from Wald test for significance of the HR comparing Haiti versus Miami (Ref) derived from Cox regression models.

§P value from Wald test for significance of the HR derived from Fine and Gray regression models taking into account death from other causes as competing risk.

¶Adjusted HR comparing Haiti versus Miami (Ref), from multivariable models including age (> v < 50 years) and body mass index (> v < 30 kg/m²). In the analysis of all patients, we also included stage at disease presentation (IV v 0-III).
rate is low compared with national averages, which were reported to be 66.8% for NHW and 67.1% for NHB in 2013. Barriers for health care utilization cited for this cohort included lack of health insurance coverage, lack of health education, communication and language barriers, and concerns about immigration status. Other factors that have been described for BC total delay include low socioeconomic factors, ethnic minorities, travel time to hospital, long waiting times to get medical appointments, and consulting three or more different health services before arrival to a cancer center.

Table 3. Age, Disease Stage, and Receptor Status at Diagnosis of Our Study Cohorts Compared With Data Extracted From the SEER Database From 2008 to 2012 for Non-Hispanic Black and Non-Hispanic White Women

| Characteristic          | Haitians in Haiti (n = 94) | Haitians in Miami (n = 102) | Non-Hispanic Black Women (n = 35,285) | Non-Hispanic White Women (n = 232,072) |
|-------------------------|---------------------------|-----------------------------|---------------------------------------|---------------------------------------|
| Age at diagnosis, years |                           |                             |                                       |                                       |
| < 40                    | 22.3                      | 7.8                         | 6.5                                   | 3.3                                   |
| 40-49                   | 28.7                      | 26.5                        | 19.2                                  | 14.9                                  |
| 50-59                   | 28.7                      | 39.2                        | 27.8                                  | 23.8                                  |
| ≥ 60                    | 20.2                      | 26.5                        | 46.5                                  | 57.9                                  |
| < 50                    | 51.1                      | 34.3                        | 25.7                                  | 18.3                                  |
| ≥ 50                    | 48.9                      | 65.7                        | 74.3                                  | 81.7                                  |
| Mean (SD)               | 50.2 (12.9)               | 53.7 (11.1)                 | 58.8 (13.2)                           | 62.4 (13.3)                           |
| Median                  | 48.5                      | 54                          | 58                                    | 62                                    |
| Interquartile range     | 41-58                     | 47-60                       | 49-58                                 | 52-72                                 |
| Range                   | 27-89                     | 27-88                       | 18-108                                | 18-114                                |
| Cancer stage            |                           |                             |                                       |                                       |
| 0 (DCIS)                | 1.1                       | 13.7                        | 18.4                                  | 17.2                                  |
| I                       | 2.1                       | 14.7                        | 31.2                                  | 42.9                                  |
| II                      | 24.5                      | 27.5                        | 31.1                                  | 27.0                                  |
| III                     | 44.7                      | 25.5                        | 13.3                                  | 9.0                                   |
| IV                      | 27.6                      | 18.6                        | 5.9                                   | 3.8                                   |
| Receptor status         |                           |                             |                                       |                                       |
| ER, No.                 | 49                        | 35,278                      | 232,029                               |
| Negative                | 44.9                      | 26.5                        | 26.9                                  | 15.7                                  |
| Positive                | 55.1                      | 73.5                        | 73.1                                  | 84.3                                  |
| PR, No.                 | 34                        | 34,930                      | 229,161                               |
| Negative                | 64.7                      | 40.2                        | 38.8                                  | 27.1                                  |
| Positive                | 35.3                      | 59.8                        | 61.2                                  | 72.9                                  |
| ER/PR, No.              | 42                        |                             |                                       |                                       |
| Both negative           | 35.7                      | 26.5                        | 25.3                                  | 14.9                                  |
| Either one or both positive* | 64.3              | 73.5                        | 74.7                                  | 85.1                                  |
| HER2,† No.              | 25                        | 17,988                      | 116,992                               |
| Negative                | 72.0                      | 80.4                        | 80.3                                  | 83.9                                  |
| Positive*               | 28.0                      | 19.6                        | 19.7                                  | 16.1                                  |
| Triple-negative status, No. | 40                | 31,147                      | 214,439                               |
| Yes                     | 17.5                      | 21.6                        | 11.9                                  | 5.5                                   |
| No                      | 82.5                      | 78.4                        | 88.1                                  | 94.5                                  |

Abbreviations: DCIS, ductal carcinoma in situ; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; SD, standard deviation.
*Positive includes borderline.
†HER2 status available in SEER for patients diagnosed in 2010 and later.
It is unclear why the native Haitians in our study presented with more ER-negative disease than the immigrant Haitian women. The triple-negative rate in native Haitians with known receptor status was 44.9% compared with 26.5% in Haitians in Miami. The rate of triple-negative BC was similar between Haiti immigrants and African American women (26.5% vs 28.4%, respectively). These rates remain significantly elevated compared with the 15.2% rate of triple-negative BC reported in NHW women. All ER and HER2 testing was performed in the United States, so the testing was consistent and accurate, although there may be some effect from storage or preservation of the Haitian samples that influenced the rate of positive ER tests.

There are distinct differences in the age of BC presentation in the four cohorts. The women in our study who lived in Haiti had symptoms for almost 2 years before presentation, which argues that the age of onset is actually younger than stated and that the age difference is greater than what we document. One explanation is that the life expectancy in Haiti is 61 years, which means that women die of competing causes of mortality before they reach ages where BC incidence increases. The average age of a Haitian immigrant is 45 years, which is younger than the average age of BC onset in Haiti. Thus, it seems that women immigrate before the average age of BC onset. According to institutional data, 96% of Haitian women seeking care at JMH immigrated within 5 years.\textsuperscript{15} Research shows that environmental and behavioral factors in Westernized countries, such as smoking, nutrition, physical inactivity, and fertility factors, increase the incidence of hereditary and sporadic BC in immigrants over a prolonged period.\textsuperscript{19-21} Short-term effects of immigration on BC development have never been documented.

Our study suggests that Afro-Caribbean women from Haiti have different age of onset and tumor characteristics than NHB women reported in SEER data. Recently, members of our research group found that other Afro-Caribbean women develop BC at an earlier age than either European American or African American women.\textsuperscript{22} Taioli et al\textsuperscript{23} found that Caribbean women living in Brooklyn are diagnosed at an older age than women from the Caribbean territories. The Afro-Caribbean population has extremely diverse ancestry, with populations with deep genetic roots in West Africa, northern Europe, the Indian subcontinent, China, the Middle East, and southern Europe and native Caribbean populations. The different ethnicities within African descents are distinct in terms of beliefs, behaviors, risk factors, and disease experience, which have an impact on the accurate use of this term for epidemiologic and public health research.\textsuperscript{24-26}

In conclusion, Haitians diagnosed with BC in Haiti experience a significantly worse outcome than Haitian immigrants in Miami, which seems to be related to a more advanced stage and younger age at diagnosis, more ER-negative tumors, and lack of timely effective treatments. In addition, there are differences in the age of presentation and ER-positive status that raise the question of whether there are disparities within subgroups of women of African origin. Confounding epigenetic-related variables and other environmental factors might impact survival and need further exploration.

DOI: https://doi.org/10.1200/JGO.2016.005975
Published online on jgo.org on November 2, 2016.

**AUTHOR CONTRIBUTIONS**

Conception and design: Alexandra Gomez, Judith Hurley
Administrative support: Vincent DeGennaro, Judith Hurley
Provision of study materials or patients: Vincent DeGennaro, Judith Hurley
Collection and assembly of data: Alexandra Gomez, Vincent DeGennaro, Estefania Santamaria, Gustavo Figueiredo Westin, Dieudina Gabriel, Judith Hurley
Data analysis and interpretation: Alexandra Gomez, Vincent DeGennaro, Sophia H.L. George, Isildinha M. Reis, Judith Hurley
Manuscript writing: All authors

**Final approval of manuscript:** All authors
**Accountable for all aspects of the work:** All authors

**AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.
Alexandra Gomez
No relationship to disclose

Vincent DeGennaro
No relationship to disclose

Sophia H.L. George
No relationship to disclose

Isildinha M. Reis
No relationship to disclose

Estefania Santamaria
No relationship to disclose

Gustavo Figueiredo Westin
No relationship to disclose

Dieudina Gabriel
No relationship to disclose

Judith Hurley
No relationship to disclose

Affiliations
Alexandra Gomez, Gustavo Figueiredo Westin, and Judith Hurley, University of Miami/Jackson Memorial Hospital; Sophia H.L. George, Sylvester Comprehensive Cancer Center, University of Miami; Isildinha M. Reis, Sylvester Biostatistics and Bioinformatics Core Resource, University of Miami, Miami; Vincent DeGennaro and Estefania Santamaria, University of Florida College of Medicine, Gainesville, FL; and Vincent DeGennaro and Dieudina Gabriel, Innovating Health International, Port-au-Prince, Haiti.

REFERENCES
1. Ferlay J, Soerjomataram I, Ervik M, et al: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11, 2013 ed. Lyon, France, International Agency for Research on Cancer, 2013. http://globocan.iarc.fr
2. Ferlay J, Soerjomataram I, Dikshit R, et al: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359-E386, 2015
3. Torre LA, Siegel RL, Ward EM, et al: Global cancer incidence and mortality rates and trends: An update. Cancer Epidemiol Biomarkers Prev 25:16-27, 2016
4. Ward E, Jemal A, Okokonides V, et al: Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin 54:78-93, 2004
5. Department of Homeland Security, Office of Immigration Statistics: U.S. Yearbook of Immigration Statistics: 2013. Washington, DC, Department of Homeland Security, Office of Immigration Statistics, 2014
6. Sohmer R: The Haitian Community in Miami Dade. Growing the Middle Class: Connecting All Miami-Dade Residents to Economic Opportunity. Washington, DC, The Brookings Institution Metropolitan Policy Program, 2010
7. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
8. Unger-Saldaña K: Challenges to the early diagnosis and treatment of breast cancer in developing countries. World J Clin Oncol 5:465-477, 2014
9. Kothari A, Fentiman IS: 22. Diagnostic delays in breast cancer and impact on survival. Int J Clin Pract 57:200-203, 2003
10. Arndt V, Stürmer T, Stegmaier C, et al: Patient delay and stage of diagnosis among breast cancer patients in Germany: A population based study. Br J Cancer 86:1034-1040, 2002
11. Richards MA, Smith P, Ramirez AJ, et al: The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. Br J Cancer 79:858-864, 1999
12. Gorin SS, Heck JE, Cheng B, et al: Delays in breast cancer diagnosis and treatment by racial/ethnic group. Arch Intern Med 166:2244-2252, 2006
13. Balasubramanian BA, Demissie K, Crabtree BF, et al: Black Medicaid beneficiaries experience breast cancer treatment delays more frequently than whites. Ethn Dis 22:288-294, 2012
14. McGee SA, Durham DD, Tse CK, et al: Determinants of breast cancer treatment delay differ for African American and white women. Cancer Epidemiol Biomarkers Prev 22:1227-1238, 2013
15. Seay JS, Carrasquillo O, Campos NG, et al: Cancer screening utilization among immigrant women in Miami, Florida. Prog Community Health Partnersh 9:11-20, 2015 (suppl)
16. Centers for Disease Control and Prevention, National Center for Health Statistics: Health, United States, 2014: With special feature on adults aged 55-64. http://www.cdc.gov/nchs/data/hus/hus14.pdf#076
17. Sambamoorthi U, McAlpine DD: Racial, ethnic, socioeconomic, and access disparities in the use of preventive services among women. Prev Med 37:475-484, 2003
18. Kobetz E, Menard J, Diem J, et al: Community-based participatory research in Little Haiti: Challenges and lessons learned. Prog Community Health Partnersh 3:133-137, 2009
19. Nodora JN, Gallo L, Cooper R, et al: Reproductive and hormonal risk profile according to language acculturation and country of residence in the Ella Binational Breast Cancer Study. J Womens Health (Larchmt) 23:532-540, 2014

20. John EM, Phipps AI, Davis A, et al: Migration history, acculturation, and breast cancer risk in Hispanic women. Cancer Epidemiol Biomarkers Prev 14:2905-2913, 2005

21. Andreeva VA, Unger JB, Pentz MA: Breast cancer among immigrants: A systematic review and new research directions. J Immigr Minor Health 9:307-322, 2007

22. George SA, Donenberg T, Albari M, et al: Breast cancer in the Caribbean: A six-country cohort. 8th American Association for Cancer Research Conference of the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, Atlanta, GA, November 12-16, 2015

23. Taioli E, Attong-Rogers A, Layne P, et al: Breast cancer survival in women of African descent living in the US and in the Caribbean: Effect of place of birth. Breast Cancer Res Treat 122:515-520, 2010

24. Agyemang C, Bhopal R, Bruijnzeels M: Negro, black, black African, African Caribbean, African American or what? Labelling African origin populations in the health arena in the 21st century. J Epidemiol Community Health 59:1014-1018, 2005

25. Aspinall PJ: The categorization of African descent populations in Europe and the USA: Should lexicons of recommended terminology be evidence-based? Public Health 122:61-69, 2008

26. Oppenheimer GM: Paradigm lost: Race, ethnicity, and the search for a new population taxonomy. Am J Public Health 91:1049-1055, 2001